Form 4: Protagonist Therapeutics CEO Sells Shares Under Pre-Arranged Plan

Protagonist Therapeutics' President and CEO, Dinesh V. Patel, Ph.D., sold 10,415 shares of common stock for a weighted average price of $54.78 per share under a Rule 10b5-1 trading plan.

Summary

• Dinesh V. Patel, Ph.D., who serves as Director, President, and CEO of Protagonist Therapeutics, Inc. (PTGX), reported a sale of common stock.
• The transaction involved the disposition of 10,415 shares of common stock.
• The shares were sold at a weighted average price of $54.78 per share, with individual sales ranging from $54.75 to $54.82.
• The total value of shares sold was approximately $570,498.70.
• Following this transaction, Dinesh V. Patel, Ph.D., beneficially owns 520,603 shares of common stock.
• The sale was conducted on July 25, 2025, and was reported on July 28, 2025.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates the negative signal often associated with discretionary insider selling, making it a routine transparency filing.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction and not a discretionary sale based on recent non-public information, which can mitigate negative investor perception often associated with insider selling.

Negatives

• A high-level executive, the President and CEO, reduced their direct equity stake in the company by selling 10,415 shares.

Risks

• While executed under a 10b5-1 plan, any insider selling, particularly by a CEO, can sometimes be perceived negatively by investors, potentially leading to minor downward pressure on stock price or sentiment.

Future Outlook

This filing, a Form 4, reports a past insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction report for a biotechnology company. Such filings are common and provide transparency into executive stock ownership changes. The use of a 10b5-1 plan is a standard practice for executives to manage their stock holdings in a pre-planned, compliant manner.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership changes. The pre-planned nature of the sale may alleviate concerns about the executive's confidence in the company's future.

Key Dates

Recommendation

This Form 4 filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan. Such transactions are typically not indicative of new fundamental information about the company's performance or outlook. Therefore, this filing alone does not provide a basis for a change in investment recommendation, and a 'hold' stance is appropriate as it does not alter the underlying investment thesis.

Keywords

Protagonist Therapeutics, PTGX, Dinesh V. Patel, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Common Stock